PROBLEM TO BE SOLVED: To provide pharmaceutical compositions for administration to a patient suffering from diabetes and other metabolic disorders.SOLUTION: The invention provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase； a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a C-terminal fragment of the β subunit of human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase； and a pharmaceutical composition comprising pharmaceutically acceptable solid carrier, a) an activated-potentiated form of an antibody to a C-terminal fragment of the β subunit of human insulin receptor in the form of a mixture of C12, C30, and C200 homeopathic dilutions impregnated into the solid carrier, and b) activated-potentiated form of an antibody to endothelial NO-synthase in the form of mixture of C12, C30, and C200 homeopathic dilutions impregnated into the solid carrier.SELECTED DRAWING: Figure 1【課題】糖尿病及び他の代謝障害に罹っている患者に投与するための医薬組成物の提供。【解決手段】ａ）ヒトインスリン受容体に対する活性化増強型抗体と、ｂ）内皮ＮＯ合成酵素に対する活性化増強型抗体とを含む医薬組成物。ａ）ヒトインスリン受容体β－サブユニットのＣ末端断片に対する活性化増強型抗体と、ｂ）内皮ＮＯ合成酵素に対する活性化増強型抗体とを含むことを特徴とする医薬組成物。薬学的に許容される固体担体と、ａ）前記固体担体に浸透させたＣ１２、Ｃ３０、及びＣ２００ホメオパシー希釈物の混合物の形態であるヒトインスリン受容体β－サブユニットのＣ末端断片に対する活性化増強型抗体と、ｂ）前記固体担体に浸透させたＣ１２、Ｃ３０、及びＣ２００ホメオパシー希釈物の混合物の形態である内皮ＮＯ合成酵素に対する活性化増強型抗体とを含むことを特徴とする医薬組成物。【選択図】図１
